These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11005773)

  • 21. The cost effectiveness of misoprostol prophylaxis alongside long-term nonsteroidal anti-inflammatory drugs. Implications of the MUCOSA trial.
    Davey PJ; Meyer E
    Pharmacoeconomics; 2000 Mar; 17(3):295-304. PubMed ID: 10947304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy of non-steroidal antirheumatic drug-induced gastrointestinal lesions with misoprostol].
    Bach GL; Stock KP; Hüdepohl M
    Z Rheumatol; 1991; 50(3):175-80. PubMed ID: 1927064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of NSAID-induced gastroduodenal ulcers.
    Rostom A; Wells G; Tugwell P; Welch V; Dube C; McGowan J
    Cochrane Database Syst Rev; 2000; (4):CD002296. PubMed ID: 11034748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diclofenac/misoprostol: the European clinical experience.
    McKenna F
    J Rheumatol Suppl; 1998 May; 51():21-30. PubMed ID: 9596551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
    de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
    Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?
    Elliott RA; Hooper L; Payne K; Brown TJ; Roberts C; Symmons D
    Rheumatology (Oxford); 2006 May; 45(5):606-13. PubMed ID: 16368733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs.
    Gabriel SE; Campion ME; O'Fallon WM
    Arthritis Rheum; 1994 Mar; 37(3):333-41. PubMed ID: 8129789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of misoprostol in Sweden.
    Jönsson B; Haglund U
    Int J Technol Assess Health Care; 1992; 8(2):234-44. PubMed ID: 1628906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescribing rationale and budgetary outcomes associated with the introduction of a combined formulation of diclofenac sodium and misoprostol in Canada.
    Sclar DA; Robison LM; Maheu A; Skaer TL
    J Int Med Res; 1995; 23(6):439-48. PubMed ID: 8746611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
    Deeks JJ; Smith LA; Bradley MD
    BMJ; 2002 Sep; 325(7365):619. PubMed ID: 12242171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
    Yun HR; Bae SC
    Rheumatol Int; 2005 Jan; 25(1):9-14. PubMed ID: 13680139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety of Arthrotec in patients with rheumatoid arthritis or osteoarthritis: an assessment of the upper gastrointestinal tract by endoscopy.
    de Melo Gomes JA
    Scand J Rheumatol Suppl; 1992; 96():23-31. PubMed ID: 1439621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arthrotec: the evidence speaks for itself.
    Morgan D
    Scand J Rheumatol Suppl; 1999; 109():13-8. PubMed ID: 10422542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs.
    Knill-Jones R; Drummond M; Kohli H; Davies L
    Postgrad Med J; 1990 Aug; 66(778):639-46. PubMed ID: 2120690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Misoprostol (Cytotec) in NSAID gastropathy.
    Habibullah CM; Singh SP; Phaterpekar SJ
    J Assoc Physicians India; 1993 Nov; 41(11):770. PubMed ID: 8005958
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
    Salentijn GJ
    Ned Tijdschr Geneeskd; 1999 Nov; 143(46):2340. PubMed ID: 10589227
    [No Abstract]   [Full Text] [Related]  

  • 37. Economic evaluation of prophylactic treatment with Misoprostol in osteoarthritic patients treated with NSAIDs. The case of Belgium.
    Carrin GJ; Torfs KE
    Rev Epidemiol Sante Publique; 1990; 38(3):187-99. PubMed ID: 2118670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A decision analysis model in the evaluation of NSAIDs in a managed care setting: a case study.
    Brixner DI
    Med Interface; 1994 Nov; 7(11):145-50. PubMed ID: 10138701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs.
    Rahme E; Joseph L; Kong SX; Watson DJ; Pellissier JM; LeLorier J
    Pharmacoeconomics; 2001; 19(5 Pt 2):577-88. PubMed ID: 11465302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group.
    Bocanegra TS; Weaver AL; Tindall EA; Sikes DH; Ball JA; Wallemark CB; Geis GS; Fort JG
    J Rheumatol; 1998 Aug; 25(8):1602-11. PubMed ID: 9712107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.